Neurobiology of Aging
Volume 31, Issue 3 , Pages 357-367 , March 2010

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

  • Oskar Hansson

      Affiliations

    • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
    • Neuropsychiatric Clinic, Malmö University Hospital, S-20502 Malmö, Sweden
    • Corresponding Author InformationCorresponding author at: Neuropsychiatric Clinic, Malmö University Hospital, S-20502 Malmö, Sweden. Tel.: +46 40 335036; fax: +46 40 334604.
    • ,
  • Henrik Zetterberg

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Göteborg University, Sweden
    • ,
  • Eugeen Vanmechelen

      Affiliations

    • Innogenetics, Ghent, Belgium
    • ,
  • Hugo Vanderstichele

      Affiliations

    • Innogenetics, Ghent, Belgium
    • ,
  • Ulf Andreasson

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Göteborg University, Sweden
    • ,
  • Elisabet Londos

      Affiliations

    • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
    • Neuropsychiatric Clinic, Malmö University Hospital, S-20502 Malmö, Sweden
    • ,
  • Anders Wallin

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Göteborg University, Sweden
    • ,
  • Lennart Minthon

      Affiliations

    • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
    • Neuropsychiatric Clinic, Malmö University Hospital, S-20502 Malmö, Sweden
    • ,
  • Kaj Blennow

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, Göteborg University, Sweden

Received 30 October 2007 ,Revised 25 March 2008 ,Accepted 26 March 2008.

References 

  1. Association AP. Diagnostic and Statistical Manual of Mental Disorders. third ed. revised. Arlington, VA, USA: American Psychiatric Association; 1987;
  2. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 1996;271(51):32916–32922
  3. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging. 2008;29(1):1–11
  4. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605–613
  5. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387–403
  6. Brun A, Englund E, Gustafson L, Passant U, Mann D, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 1994;57(4):416–418
  7. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295(5563):2264–2267
  8. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J. Neurol. Transm. Suppl. 2000;59:23–30
  9. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006;59(3):512–519
  10. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J. Neuropathol. Exp. Neurol. 2007;66(4):264–271
  11. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 2003;60(7):958–964
  12. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006;367(9518):1262–1270
  13. Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, et al. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct. Genomic Proteomic. 2007;6(2):149–158
  14. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007;64(3):354–362
  15. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234
  16. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007;23(5):316–320
  17. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42 (43). Neurology. 1997;48(3):741–745
  18. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1999;257(3):787–791
  19. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 1999;46(3):412–416
  20. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185–1190
  21. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 1999;53(5):902–905
  22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  23. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 2000;57(1):100–105
  24. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 2001;304(1–2):102–106
  25. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J. Neurol. Neurosurg. Psychiatry. 2005;76(11):1485–1490
  26. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321–332
  27. Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006;20(24):3723–3735
  28. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2005;51(2):336–345
  29. Palmer K, Backman L, Winblad B, Fratiglioni L. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ. 2003;326(7383):245
  30. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging. 2006;27(6):904–905
  31. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Int. Med. 2004;256(3):183–194
  32. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56(3):303–308
  33. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am. J. Geriatr. Psychiatry. 2005;13(10):914–917
  34. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology. 2004;62(11):2116–2118
  35. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260
  36. Sacuiu S, Sjogren M, Johansson B, Gustafson D, Skoog I. Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology. 2005;65(12):1894–1900
  37. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 2007;13(9):1029–1031
  38. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476–481
  39. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2(8):864–870
  40. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66(4):602–604
  41. Sobow T, Flirski M, Kloszewska I, Liberski PP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol. Exp. (Wars). 2005;65(2):117–124
  42. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652–656
  43. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 1996;141(1–2):65–68
  44. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655–660
  45. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7(4):245–258
  46. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 2005;33(Pt 5):1087–1090
  47. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002;81(3):481–496
  48. Zetterberg H, Blennow K. Plasma Abeta in Alzheimer's disease—up or down?. Lancet Neurol. 2006;5(8):638–639

PII: S0197-4580(08)00131-0

doi: 10.1016/j.neurobiolaging.2008.03.027

Neurobiology of Aging
Volume 31, Issue 3 , Pages 357-367 , March 2010

Article Tools

* Image Usage & Resolution